ISA Pharmaceuticals B.V. (Isa)

Oncology Corporate Profile

HQ Location

J.H. Oortweg 19
NL-2333 CH Leiden, The Netherlands

Company Description

SA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT® technology, which have the potential to generate safe and effective immunologic responses with a known mechanism of action. Synthetic long peptides are broadly applicable to multiple targets and ideally suited for monotherapy, as essential components in combination with conventional cancer treatments, and with novel immunomodulators such as Nivolumab. SLP® immunotherapies are designed to fully harness and direct the body's own defenses towards fighting the disease.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ISA101immunotherapyCervical cancerI
ISA201immunotherapyHead & Neck cancerI
ISA203immunotherapyVarious cancer typesI

View additional information on product candidates here »


Recent News Headlines

Eisai Latest Cancer Drugmaker To Win UK Approval After Price Cut

11/3/2016 04:42 pm

(Reuters) Nov 2, 2016 - Cancer drugmakers are cutting prices to ensure their medicines are used routinely on Britain's National Health Service, following the overhaul of a cancer drug funding scheme, with Japan's Eisai the latest to win approval.

Bristol-Myers Partner Ono Drops as Cancer Drug Data Disappoint

10/11/2016 05:12 pm

(Bloomberg) Oct 10, 2016 - Ono Pharmaceutical Co. shares dropped in Japan trading after its partner Bristol-Myers Squibb Co. released study results for its immune-based therapy Opdivo that fell short of already low expectations in a lung cancer trial that studied wider use of the drug.

Bristol-Myers Lung-Cancer Drug Disappoints in Trial Analysis

10/10/2016 11:24 am

(Bloomberg) Oct 9, 2016 - Bristol-Myers Squibb Co.’s immune-based therapy Opdivo fell short of already low expectations in study results that throw into question whether the drug can help lung-cancer patients who’ve just been diagnosed.

Research Finds Talc Doesn’t Cause Cancer; Juries Disagree

9/26/2016 04:24 pm

(Seattle Times/Associated Press) Sept 26, 2016 - Two lawsuits ended in jury verdicts worth $127 million. Two others were tossed out by a judge who said there wasn’t reliable evidence that the talc in Johnson & Johnson’s iconic baby powder causes ovarian cancer. So who’s right? And is baby powder safe?

Novartis Says MS Drug Cut Risk Of Disability Advance In Study

9/19/2016 04:52 pm

(Reuters) Sept 17, 2016 - Novartis's investigational multiple sclerosis drug cut the risk of disability progression in patients with a tough-to-treat form of the disease versus a placebo, the Swiss company said on Saturday, citing a new analysis of a late-stage trial.

Bipartisan Bill In Congress Would Require Drug Makers To Justify, Limit Price Hikes

9/16/2016 04:49 pm

(STAT/Pharmalot) Sept 15, 2016 - In response to the intensifying outrage over the cost of medicines, a bipartisan group of lawmakers Thursday introduced a bill that would require drug makers to justify their pricing and provide a breakdown of their costs before raising prices on certain products by more than 10 percent.

Eisai's Kisplyx Approved in EU for Kidney Cancer

9/15/2016 05:05 pm

(PharmaTimes [UK]) Sept 15, 2016 - The European Commission has stamped its approval on the use of Eisai's Kisplyx to treat advanced kidney cancer.

German Pricing Rules Hit Eisai’s Halaven

9/6/2016 03:51 pm

(pharmaphorum [UK]) Sept 5, 2016 - Eisai may have to sell its Halaven (eribulin) at rock-bottom prices in its new advanced liposarcoma use in Germany after a cost-effectiveness body found it offered “no additional benefit” compared with standard care.

Fingerprints Disappear During Capecitabine Therapy

8/30/2016 04:23 pm

(Medscape Medical News) Aug 29, 2016 - The commonly used chemotherapy agent capecitabine can leave many patients without fingerprints, but the effect is temporary.

When DNA and Medical Tests Disagree About Breast Cancer Risk, Which to Believe?

8/25/2016 11:57 am

(STAT) Aug 24, 2016 - It’s a dilemma more and more cancer patients will face as genetic testing becomes part of everyday health care: When a DNA test indicates low risk of a tumor spreading, but traditional tests show a high risk, which do you believe?

Notice of Intended Ordering of Supervisory Measures

8/11/2016 02:00 pm

[at noodls] - Pursuant to the Rules of the Ljubljana Stock Exchange, Ljubljana, Sava Reinsurance Company, d.d., Ljubljana hereby announces the following: Sava Reinsurance Company, d.d., (hereinafter: Company) received ...

Eisai: FDA Confirms Enough Data To Move Alzheimer's Drug To Phase III Studies

8/9/2016 04:23 pm

(Reuters) Aug 9, 2016 - Japan's Eisai Co said on Tuesday the U.S. Food and Drug Administration had confirmed that there was sufficient data to start Phase III studies of a drug it is co-developing to treat early Alzheimer's disease.

Eisai, NHS and NICE Fail To Reach Deal On Lenvima

8/2/2016 04:15 pm

(PharmaTimes [UK]) Aug 2, 2016 - Patients with an advanced form thyroid cancer may have to wait three years for NHS access to Eisai's Lenvima in England, after the drug was left out of the newly launched Cancer Drugs Fund.

JAMA Forum: The Partisan Divide on Health Care

7/29/2016 04:17 pm

(news@JAMA) July 27, 2016 - Presidential elections rarely turn on debates over policy. They are typically influenced much more by the state of the economy, what is happening in the world, and the personal characteristics of the candidates.

Eisai And Halozyme Initiate Phase 1b/2 Clinical Trial With First Patient Dosing Of Eribulin In Combination With PEGPH20

7/26/2016 04:13 pm

(Yahoo! Finance) July 26, 2016 - Halozyme Therapeutics, Inc. announced today that Eisai Inc. has dosed the first patient in a collaborative phase 1b/2 clinical trial to assess whether Eisai's eribulin mesylate (HALAVEN®) in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) can improve overall response rate (ORR) – the proportion of women that have a predefined reduction in tumor burden – as compared with eribulin alone as a therapy in women with advanced or metastatic, High-Hyaluronan (HA) HER2-negative breast cancer.

Eisai Urges Action On Rare Cancer Drugs ‘Black Hole’

7/12/2016 12:19 pm

(PharmaTimes [UK]) July 12, 2016 - Patients with thyroid cancer could be waiting three years for access to Eisai's Lenvima because the drug was left out of the re-launched Cancer Drugs Fund (CDF) and NICE guidance is not to be published until 2018.

Japan's Eisai Weighs Legal Action In UK Cancer Drug Row

7/8/2016 04:13 pm

(Reuters) July 7, 2016 - Japan's Eisai said on Friday it would consider all options, including possible legal action, to fight delays in Britain's healthcare system that prevent patients from accessing one of its drugs to treat a rare form of cancer.

Doctor Yearns For Return To Time When Physicians Were 'Artisans'

5/24/2016 05:10 pm

(NPR/Shots blog) May 24, 2016 - In his recent book, The Finest Traditions of My Calling, Dr. Abraham Nussbaum, 41, makes the case that doctors and patients alike are being shortchanged by current medical practices that emphasize population-based standards of care rather than individual patient needs and experiences.

FDA Approves Eisai's LENVIMA (lenvatinib) for the Treatment of Patients with Advanced Renal Cell Carcinoma in Combination with Everolimus Following Prior Anti-Angiogenic Therapy

5/16/2016 12:03 pm

(Eisai) May 13, 2016 - Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved LENVIMA®(lenvatinib), the company's multiple receptor tyrosine kinase inhibitor, in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (aRCC) who were previously treated with an anti-angiogenic therapy.

The Improvisational Oncologist

5/12/2016 05:17 pm

(New York Times Magazine) May 12, 2016 - In an era of rapidly proliferating, precisely targeted treatments, every cancer case has to be played by ear.

EU Nod for Eisai's Halaven in Liposarcoma

5/5/2016 04:35 pm

(PharmaTimes [UK]) May 5, 2016 - Patients with a type of advanced tissue sarcoma called liposarcoma living in the European Union can now potentially get access to Eisai’s Halaven after regulators waved through the drug.

Laura and Isaac Perlmutter Cancer Center at NYU Langone & the Technion-Israel Institute of Technology Officially Launch Global Cancer Research Initiative

4/25/2016 04:39 pm

(NYU Langone) Apr 22, 2016 - Melanoma, mesothelioma are the focus of first joint studies.

Dr. Avinash Desai Appointed Vice President, Americas Oncology Medical Affairs, Oncology Business Group at Eisai Inc.

4/20/2016 05:30 pm

(Morningstar) Apr 20, 2016 - Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Avinash Desai, MD, as Vice President, Americas Oncology Medical Affairs for the Oncology Business Group (OBG).

Eisai's Halaven Bags EU Marketing Recommendation For Liposarcoma

4/5/2016 12:07 pm

(PharmaTimes [UK]) Apr 4, 2016 - Eisai’s breast cancer drug Halaven could soon be available in Europe to treat liposarcoma, after regulatory advisors backed expanding its use.

BTG to Initiate Multi-Centre TARGET Study Evaluating Dosimetry for 90Y Radioembolisation Therapy in Patients With Hepatocellular Carcinoma

4/4/2016 04:29 pm

(4-traders) Apr 2, 2016 - The study will evaluate two-compartment dosimetry (normal tissue and tumour absorbed dose) in hepatocellular carcinoma patients in interventional oncology in an effort towards a more personalised approach to Y radioembolisation therapy for liver cancer patients.

Dr. Reddy's Acquires Ex-Asia Rights to Eisai Anti-Cancer Agent E7777

4/1/2016 04:27 pm

(Pharmaceutical Business Review) Apr 1, 2016 - Eisai has signed an agreement to transfer the exclusive global development and commercialization rights, excluding Japan and Asia, to its cancer drug candidate E7777 to Dr. Reddy’s Laboratories.